Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Leukemia. 2009 Dec;23(12):2222-32. doi: 10.1038/leu.2009.179. Epub 2009 Sep 10.

The use of novel agents in the treatment of relapsed and refractory multiple myeloma.

Author information

  • 1Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA, USA. jacobp_laubach@dfci.harvard.edu

Abstract

Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease.

PMID:
19741729
[PubMed - indexed for MEDLINE]
PMCID:
PMC3133628
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk